Key result
Metformin remains the preferred insulin-sensitizer for PCOS given its weight, lipid, and pregnancy safety benefits.
Why the study?
Standard therapy for PCOS with oral contraceptives may aggravate long-term health risks, prompting evaluation of insulin-sensitizing drugs metformin and thiazolidinediones.
Metformin is considered the preferred insulin-sensitizing agent for managing PCOS due to its efficacy on metabolic parameters and safety profile.
Answers are grounded in this paper and cite their sources.
Reinforces metformin preference in PCOS management; leaves open head-to-head trials versus newer agents.
Polycystic ovary syndrome (PCOS) is a common and prevalent disorder associated with important short-term and long-term health consequences. Standard therapy has consisted of oral contraceptives, but these may aggravate long-term health risks. Emerging therapy for the syndrome is the use of insulin-sensitizing drugs, namely the biguanide metformin and the thiazolidinediones. These drugs may improve not only the anovulation and hyperandrogenism of the disorder, but they may also exert salutary effects on the dysmetabolic syndrome and decrease the long-term risks of type 2 diabetes and cardiovascular disease. Among the insulin-sensitizing drugs, metformin is currently the agent of choice because of the weight of scientific evidence in managing the syndrome, its effects on weight and lipids, and its reassuring safety profile during pregnancy.
No takes yet. Share an insight, caveat, or question.
Baillargeon et al. (2002) conducted a review in Polycystic ovary syndrome (PCOS). Metformin and thiazolidinediones vs. Oral contraceptives was evaluated. Metformin is considered the agent of choice among insulin-sensitizing drugs for managing polycystic ovary syndrome due to its evidence base, effects on weight and lipids, and safety during pregnancy.
Synapse has enriched 10 related papers. Consider them for comparative context: